Tags

Type your tag names separated by a space and hit enter

Successful migraine prophylaxis with naproxen sodium.
Neurology 1985; 35(9):1304-10Neur

Abstract

Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

4022376

Citation

Welch, K M., et al. "Successful Migraine Prophylaxis With Naproxen Sodium." Neurology, vol. 35, no. 9, 1985, pp. 1304-10.
Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35(9):1304-10.
Welch, K. M., Ellis, D. J., & Keenan, P. A. (1985). Successful migraine prophylaxis with naproxen sodium. Neurology, 35(9), pp. 1304-10.
Welch KM, Ellis DJ, Keenan PA. Successful Migraine Prophylaxis With Naproxen Sodium. Neurology. 1985;35(9):1304-10. PubMed PMID: 4022376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful migraine prophylaxis with naproxen sodium. AU - Welch,K M, AU - Ellis,D J, AU - Keenan,P A, PY - 1985/9/1/pubmed PY - 1985/9/1/medline PY - 1985/9/1/entrez SP - 1304 EP - 10 JF - Neurology JO - Neurology VL - 35 IS - 9 N2 - Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/4022376/full_citation L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=4022376.ui DB - PRIME DP - Unbound Medicine ER -